Long-term ranibizumab beneficial for macular edema

Long-term ranibizumab beneficial for macular edema
Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness and improved best-corrected visual acuity, according to research published online Oct. 8 in the Archives of Ophthalmology.

(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according to research published online Oct. 8 in the Archives of Ophthalmology.

Diana V. Do, M.D., of the Wilmer Eye Institute at the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a follow-up of outcomes from the for Edema of the Macula in Diabetes study from year two (month 24) to year three (month 36) to assess the benefit of increased follow-up. Participants included 28 patients who received ranibizumab (0.5 mg monthly if FTH was 250 µm or greater), 22 patients who received laser treatment, and 24 patients who received ranibizumab plus laser treatment.

The researchers found that ranibizumab-treated patients displayed a significant mean BCVA improvement of 10.3 letters at month 36 compared with only 7.2 letters at month 24. Mean FTH was reduced from 352 to 282 µm at months 36 and 24, respectively. No statistically significant difference was observed for BCVA and FTH between the ranibizumab-plus-laser group and the laser-only group. However, ranibizumab-treated patients required significantly more injections than laser-treated patients (5.4 versus 2.3 injections), but not significantly more than the ranibizumab-plus-laser group.

"Long-term visual outcomes for treatment of with ranibizumab are excellent, but many patients require frequent injections to optimally control edema and maximize vision," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Multidose eye drop approach approved by joint commission

Dec 14, 2014

(HealthDay)—A policy and procedural approach to the use of multidose eye drops has been approved by The Joint Commission and can reduce costs for patients and facilities, according to an article published ...

Retina's cancer-like metabolism could lead to new treatments

Dec 05, 2014

Eye surgeons at the University of Adelaide have discovered that the retina in human eyes uses energy in a very similar way to cancer, which could lead to improved understanding of cancers as well as eye disease such as macular ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.